IRD vs. RNAC, INZY, LFCR, NGNE, PRTA, OCGN, AMRN, AARD, MDWD, and TVGN
Should you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Cartesian Therapeutics (RNAC), Inozyme Pharma (INZY), Lifecore Biomedical (LFCR), Neurogene (NGNE), Prothena (PRTA), Ocugen (OCGN), Amarin (AMRN), Aardvark Therapeutics (AARD), MediWound (MDWD), and Tevogen Bio (TVGN). These companies are all part of the "pharmaceutical products" industry.
Opus Genetics vs. Its Competitors
Cartesian Therapeutics (NASDAQ:RNAC) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their community ranking, dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.
In the previous week, Cartesian Therapeutics had 4 more articles in the media than Opus Genetics. MarketBeat recorded 6 mentions for Cartesian Therapeutics and 2 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 1.31 beat Cartesian Therapeutics' score of 1.24 indicating that Opus Genetics is being referred to more favorably in the news media.
Cartesian Therapeutics currently has a consensus price target of $43.00, indicating a potential upside of 329.57%. Opus Genetics has a consensus price target of $7.33, indicating a potential upside of 655.08%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Opus Genetics is more favorable than Cartesian Therapeutics.
Opus Genetics has lower revenue, but higher earnings than Cartesian Therapeutics. Opus Genetics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Opus Genetics has a net margin of -324.45% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat Opus Genetics' return on equity.
86.9% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 60.3% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 6.6% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Cartesian Therapeutics received 33 more outperform votes than Opus Genetics when rated by MarketBeat users. Likewise, 95.12% of users gave Cartesian Therapeutics an outperform vote while only 85.71% of users gave Opus Genetics an outperform vote.
Cartesian Therapeutics has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500.
Summary
Cartesian Therapeutics beats Opus Genetics on 12 of the 18 factors compared between the two stocks.
Get Opus Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Opus Genetics Competitors List
Related Companies and Tools
This page (NASDAQ:IRD) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy IRD Stock Free IRD Stock Alerts